ASTACEF-CV 325

(Cefpodoxime Proxetil + Clavulanic Acid)

Broad-Spectrum Beta-Lactamase Protected Therapy

 PRODUCT INTRODUCTION

Brand Name: ASTACEF-CV 325
Generic Name: Cefpodoxime Proxetil + Clavulanic Acid
Category: Cephalosporin + Beta-Lactamase Inhibitor Combination

 

CLINICAL BACKGROUND

Common clinical challenges:

• Recurrent RTI
• ENT infections
• UTI
• Increasing beta-lactamase resistance
• Inadequate response to plain cephalosporins

Clavulanic acid enhances antibiotic effectiveness by inhibiting beta-lactamase enzymes.

MODE OF ACTION (MOA)

🔹 Cefpodoxime

• Third-generation cephalosporin
• Inhibits bacterial cell wall synthesis
• Bactericidal action

🔹 Clavulanic Acid

• Beta-lactamase inhibitor
• Protects cefpodoxime from enzymatic destruction

Combined Effect:

✔ Extended bacterial coverage
✔ Effective against beta-lactamase producing organisms
✔ Improved cure rate

 INDICATIONS

• Upper Respiratory Tract Infection (URTI)
• Lower Respiratory Tract Infection (LRTI)
• Sinusitis
• Tonsillitis
• Otitis media
• Urinary Tract Infection
• Skin & Soft Tissue Infection

 DOSAGE

• As prescribed by physician
• Usually twice daily
• Duration based on infection severity

 FEATURE – ADVANTAGE – BENEFIT (FAB)

🔹 Feature

Cephalosporin + Beta-lactamase inhibitor

🔹 Advantage

Enhanced coverage against resistant organisms

🔹 Benefit

Better clinical cure in recurrent infections

 USP

✔ Beta-lactamase protected formula
✔ Broad-spectrum activity
✔ Effective in resistant infections
✔ Good tissue penetration
✔ Reliable twice-daily dosing

 

 SAFETY PROFILE

• Mild GI upset
• Diarrhea possible
• Rare hypersensitivity
• Use cautiously in penicillin allergy